Alison Frances Lawton

CIK 1542650 · See Remarks · last filed 2026-05-22

Alison Frances Lawton is a corporate insider who has filed 38 SEC Form 4 insider transactions across 10 companies since 2012. The most recent filing, for DNTH, was dated May 22, 2026. Across all open-market trades the lifetime net is +$22.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $396.9K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$396.9K

Companies

10

Total Filings

38

Lifetime Open-Market Net

$22.9K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
DNTH Director $82.07 $0 4 2026-05-22
XFOR Director 96,667 $4.00 $386.7K $0 5 2024-06-11
Spyre Therapeutics, Inc. (AGLE) Delisted Director $12.01 $0 4 2023-06-30
Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Director $11.19 $0 3 2022-06-30
Kaleido Biosciences, Inc. (KLDO) Delisted See Remarks $0.29 $0 4 2020-04-17
VSTM Director 2,500 $4.10 $10.2K $22.9K 7 2019-06-25
CoLucid Pharmaceuticals, Inc. (CLCD) Delisted Director $0 4 2017-03-01
CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted Director 0 $0 1 2015-01-21
CUBIST PHARMACEUTICALS INC (CBST) Delisted Director 2,714 $0 4 2013-06-14
Tempest Therapeutics, Inc. (OVAS) Delisted Chief Operating Officer $0 1 2013-06-11

Recent Filings

38 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2026-05-22 DNTH Grant (A) $0 EDGAR
2025-05-22 DNTH Grant (A) $0 EDGAR
2024-06-11 XFOR Grant (A) +45,000 $0 EDGAR
2024-05-28 DNTH Grant (A) $0 EDGAR
2023-09-13 DNTH Grant (A) $0 EDGAR
2023-06-30 Spyre Therapeutics, Inc. (AGLE) Delisted Grant (A) $0 EDGAR
2023-06-14 XFOR Grant (A) +45,000 $0 EDGAR
2022-06-30 Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted Grant (A) $0 EDGAR
2022-06-27 XFOR Grant (A) +6,667 $0 EDGAR
2022-06-10 Spyre Therapeutics, Inc. (AGLE) Delisted Grant (A) $0 EDGAR
Showing 110 of 38
Page 1 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.